They discovered strong enrichment of the CD8A + tissue-resident T cell cluster across all tumor regions, along with low TAM infiltration in TME of patient complete response to ICBs, thereby establishing a CD8A + tissue-resident signature that was associated with improved efficacy with patients treated with ICBs and targeted therapy. Here, CD8A is linked to neoplasm.